November 18, 2020
Pfizer’s, Biontech’s Covid-19 vaccine candidate meets endpints in P3 trial
Pfizer’s and Biontech’s vaccine candidate for COVID-19 has met all the study’s primary efficacy endpoints.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
September 8, 2020
Novartis presentation includes new data on recently FDA-approved Kesimpta
Novartis will present 48 abstracts at the upcoming MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, September 11–13, 2020. The breadth of data being presented highlights the strength and promise of the company’s MS portfolio to improve the lives of patients across the MS spectrum.
August 7, 2020
The FDA approved an expanded indication of ViiV Healthcare’s Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 with no history of treatment failure or resistance to Dovato’s components.
July 8, 2020
Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial
Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.
July 8, 2020
Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical Announce FDA and Health Canada Approval of INQOVI® (Decitabine and Cedazuridine) Tablets, Oral Hypomethylating Agent (HMA) Therapy for Intermediate and High-Risk MDS and CMML
Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved INQOVI® (decitabine and cedazuridine) tablets. The three companies are all part of the Otsuka group of companies.
July 7, 2020
Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer
Arcus Biosciences, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer
July 7, 2020
Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules
Tenax Therapeutics in $8 million registered direct and pipe offerings priced at the market under Nasdaq rules
July 1, 2020
Gilead Sciences’ top person, Daniel O’Day on 5-day treatment course with remdesivir for $2,340 per patient
Remdevisir has become a popular word these days, along with Covid-19, Coronavirus, the city of Wuhan, and for a good reason. The headline in all the news, the pricing of remdevisir, has been flooding the internet, and pretty much the TV.
July 1, 2020
Health Canada lets certain COVID-19 patients to take NuvOx Pharma’s Oxygen therapeutic in phase II clinical trial (edit)
NuvOx Pharma ensured the continuation of Phase 2 clinical trial of its NanO2 in Covid-19 patients with acute hypoxic respiratory failure, as it got No Objection Letter from Health Canada.
June 29, 2020
Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics
Arya and Immatics’s previouslly announced business combination into combined company called Immatics N.V., has been approved by both companies’ shareholders,…